Good news travels fast

Ebb & Flow

After the spate of bad news in the sector over the past month, it's encouraging to find that investors still are willing to reward companies for good news. Aviron (AVIR) jumped $3.75 to $17.125 on Monday after releasing positive Phase III results of its intranasal flu vaccine (see BioCentury Extra, July 15). Tuesday, the stock soared $6.875 to $24 on 3.7 million shares after the data were widely publicized in both print and television media. The

Read the full 806 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE